Oxford Completes Phase 0 Trial of IGF Antibody Xentuzumab in Prostate Cancer Patients
核心洞察
The WINGMEN Phase 0 study investigated the insulin-like growth factor (搜索) antibody Xentuzumab in 27 men with prostate cancer (搜索) scheduled for radical prostatectomy.
The trial assessed feasibility of recruitment, tolerability of Xentuzumab before surgery, and generated matched pre- and post-treatment samples for molecular analyses.
Data from the study is now available on Oxford's Translational Data Platform alongside clinical, molecular and imaging data from over 1,100 trial participants across five studies.
The University of Oxford has completed the WINGMEN Phase 0 clinical trial investigating the insulin-like growth factor (搜索) (IGF (搜索)) antibody Xentuzumab in men with prostate cancer (搜索), with trial data now available through the Oxford Cancer Translational Data Platform. The study, led by Professor Simon Lord and conducted by the Oncology Clinical Trials Office, recruited 27 participants in the three to four-week window prior to their scheduled radical prostatectomy.
Novel Pre-Operative Treatment Approach
The WINGMEN trial utilized a unique pre-operative treatment window that provided researchers with an opportunity to study treatment effects before surgical intervention. This approach allowed for the generation of matched pre- and post-treatment samples, enabling detailed molecular and tissue-based analyses that would not be possible in traditional treatment settings.
The study's primary objectives focused on three key areas: assessing the feasibility of recruiting men with early prostate cancer (搜索), evaluating the tolerability of Xentuzumab before surgery, and generating comprehensive biological samples for translational research.
Expanding Translational Research Resources
The WINGMEN dataset joins a broader portfolio of trials hosted on the Translational Data Platform, which now comprises clinical, molecular and imaging data from more than 1,100 trial participants across five studies. All datasets undergo careful curation, quality control and harmonization processes to ensure research utility.
The platform enables researchers to explore, visualize and analyze data either independently or with support from the TDP team. This centralized approach to data sharing represents a significant resource for the cancer research community, facilitating collaborative research efforts and accelerating translational discoveries.
Research Access and Collaboration
Researchers interested in accessing WINGMEN data or other datasets on the Translational Data Platform can contact the platform team for further information. The availability of this curated dataset provides new opportunities for investigating IGF (搜索) pathway targeting in prostate cancer (搜索) and understanding treatment effects in the pre-operative setting.
The completion of WINGMEN adds to the growing body of evidence exploring novel therapeutic approaches in prostate cancer (搜索), particularly in the context of pre-operative treatment strategies that may inform future clinical development programs.